Form 4: ARS Pharmaceuticals' Chief Medical Officer Sarina Tanimoto Sells Shares Under 10b5-1 Plan

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, executed multiple sales of common stock between May 14 and May 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Sarina Tanimoto, the Chief Medical Officer of ARS Pharmaceuticals, sold shares of common stock between May 14 and May 16, 2024.
• The sales were executed under a Rule 10b5-1 trading plan established on March 31, 2023.
• The transactions involved sales from direct holdings as well as holdings through the Sarina Tanimoto Charitable Remainder UniTrust and the Lowenthal-Tanimoto Family Trust.
• The price per share ranged from approximately $9.00 to $9.16 across the various transactions.
• Following these transactions, Tanimoto continues to hold a significant number of shares both directly and indirectly through various trusts and spousal holdings.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity. The sentiment is neutral as it simply reports transactions under a pre-existing trading plan.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 plan suggests the sales were pre-planned and not based on any specific non-public information.

Stakeholder Impact

• The stock sales by a key executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates